Storage and Reconstitution of Vesicle Products: Procedural Risks

2026-09-10

Vesicle products, including exosomes, are sensitive to temperature and handling during storage and reconstitution. Supplier documentation may specify recommended conditions, but not all risks or handling failures are covered. Understanding procedural requirements is essential to maintain product integrity and interpret documentation claims accurately.

Why Storage and Reconstitution Matter for Vesicle Products

Vesicle products such as exosomes are sensitive biological materials. Their integrity can be compromised by temperature fluctuations, repeated freeze-thaw cycles, and improper reconstitution techniques. If storage or reconstitution protocols are not followed correctly, vesicle count, structure, and function can degrade. This affects the product’s suitability for research or further manufacturing, and any downstream analysis or use.

Supplier documentation typically provides storage temperature (often -80°C or -20°C), acceptable transport conditions, and instructions for thawing and reconstitution. However, not all potential failure points are always addressed. For example, the impact of a brief temperature excursion in transit may not be specified, nor will every certificate of analysis confirm post-arrival product integrity. Buyers must understand where the supplier’s responsibility ends and where their own handling protocols become critical.

Buyers should review supplier protocols carefully and document each step taken upon arrival. When in doubt, request clarification from the supplier on any ambiguous instruction.

What Supplier Documentation Certifies, and What It Omits

Supplier documentation, including certificates of analysis (CoA), typically certifies that the batch met certain specifications at the time of release. This may include particle concentration, protein content, sterility, and endotoxin levels. However, the CoA does not certify the product’s condition after shipping, storage at your facility, or following reconstitution. Most CoAs also do not cover effects of temperature excursions or handling errors after dispatch.

Some suppliers provide a shipping certificate confirming that temperature monitoring was in place during transit. This may list any recorded deviations. However, not all suppliers include this, and the absence of such a certificate does not imply that no excursion occurred. Buyers should verify that temperature loggers are used and request the data where possible.

After arrival, the onus is on the buyer to ensure that storage and reconstitution instructions are strictly followed. Deviations from recommended procedures can result in loss of product efficacy or reliability, which may not be detectable without specialised assays.

In summary, documentation provides a starting point, but proper handling remains the buyer’s responsibility.

Decision Rule: Assessing Product Integrity on Arrival

To minimise risk, buyers can follow an explicit decision rule when vesicle products arrive:

1. Check that the shipping container remains sealed and cold (ideally with temperature logger data).
2. Review the supplied certificate of analysis and handling instructions immediately.
3. Transfer the product to the recommended storage temperature without delay.
4. Document all handling steps, including any deviations from protocol.
5. Before use, check for visual signs of aggregation or precipitation after thawing.
6. Consider performing a quick functional or quantitative assay if available (such as nanoparticle tracking analysis or protein quantification).

Screenshot-friendly summary table:

Common Failure Modes and How to Recognise Them

Several procedural errors can compromise vesicle product quality:

• Temperature excursions: Even brief warming can disrupt vesicle membranes. Evidence of thawing or condensation on arrival should trigger caution.
• Repeated freeze-thaw cycles: Each cycle increases risk of vesicle aggregation or rupture. Most protocols specify single-use aliquots to avoid this.
• Improper reconstitution: Using water instead of the recommended buffer can cause osmotic shock. Rapid temperature changes on reconstitution may also cause aggregation.
• Extended time at room temperature: Vesicle activity can decline rapidly if left unrefrigerated, especially after thawing.

Recognising these failures may require specialised equipment. Some signs, such as visible clumping or changes in solution clarity, are accessible, but many functional changes are only detectable by laboratory analysis.

What to Do if You Suspect Product Compromise

If you believe a vesicle product has been compromised during storage or reconstitution, the first step is to document your observations, including temperature records and deviations from protocol. Contact the supplier with this information and request guidance. Some suppliers may offer replacement or additional testing, but this is not guaranteed.

Do not use the product for critical work unless its integrity can be verified. If possible, perform a rapid assay to confirm vesicle count or function. Otherwise, consider discarding the product to avoid unreliable results. Suppliers may require evidence of mishandling before considering replacement, so thorough documentation is essential.

How to Interpret Supplier Claims on Storage Stability

Supplier claims regarding storage stability are usually based on internal validation, not always on peer-reviewed evidence. The International Society for Extracellular Vesicles (ISEV) recommends that stability claims specify the tested conditions, duration, and assay used. Look for claims that reference these parameters explicitly. If a claim is vague or unsupported, ask for the underlying data or validation report.

For example, a claim such as "stable for 12 months at -80°C" is more credible if supported by data on vesicle count, protein content, and functional assays at multiple time points. Be wary of claims that do not specify the metrics or only reference visual inspection.

In the UK, claims about product stability must not mislead buyers about what is independently verified. The ASA ruling of 2024 reinforces this requirement, particularly for products used in research or manufacturing.

Limits of This Piece

This article addresses storage and reconstitution procedures for vesicle products, including exosomes, as received by buyers in the UK. It does not cover patient use, clinical outcomes, or treatment decisions, which are handled by exosomaltherapy.co.uk. It does not address polynucleotides, which are covered by polynucleotidestherapy.co.uk. The focus here is on procedural risks and supplier documentation, not on advertising claims or adjudication, which are addressed by lipozone.co.uk. This information does not apply to products already reconstituted or compounded before delivery. Always consult the original supplier documentation for product-specific protocols.